PREFER
Patient Preferences in benefit risk assessments during the drug life cycle
- Started
- 2016-10-01
- Website
- http://www.imi-prefer.eu/
Patient Preferences in benefit risk assessments during the drug life cycle
Prioritisation and risk evaluation of medicines in the environment
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
Psychiatric ratings using intermediate stratified markers 2
Physical Activity as a Crucial Patient Reported Outcome in COPD
Preparing for RSV immunisation and surveillance in Europe
Pharmacoepidemiological research on outcomes of therapeutics by a European consortium